# Amneal Pharmaceuticals, Inc.: financial statements, quarterly

AMRX · Nasdaq · CIK 1723128 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/amrx.md) · [Financials](/companies/amrx/financials.md) · [Filings](/companies/amrx/filings.md) · [Insiders](/companies/amrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/amrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [620](/filings/0001723128-24-000042.md) | [617 d](/filings/0001723128-26-000011.md) | [659](/filings/0001723128-25-000022.md) | [702](/filings/0001723128-25-000047.md) | [702](/filings/0001723128-25-000062.md) | [731 d](/filings/0001723128-26-000011.md) | [695](/filings/0001723128-26-000020.md) | [725](/filings/0001723128-26-000031.md) | [785](/filings/0001723128-25-000062.md) | [814 d](/filings/0001723128-26-000011.md) | [723](/filings/0001723128-26-000020.md) | [796](/filings/0001723128-26-000031.md) |
| Cost of revenue | $m | [388](/filings/0001723128-24-000042.md) | [427 d](/filings/0001723128-26-000011.md) | [421](/filings/0001723128-25-000022.md) | [452](/filings/0001723128-25-000047.md) | [433](/filings/0001723128-25-000062.md) | [468 d](/filings/0001723128-26-000011.md) | [440](/filings/0001723128-26-000020.md) | [438](/filings/0001723128-26-000031.md) | [511](/filings/0001723128-25-000062.md) | [517 d](/filings/0001723128-26-000011.md) | [402](/filings/0001723128-26-000020.md) | [462](/filings/0001723128-26-000031.md) |
| Gross profit | $m | [233](/filings/0001723128-24-000042.md) | [190 d](/filings/0001723128-26-000011.md) | [238](/filings/0001723128-25-000022.md) | [250](/filings/0001723128-25-000047.md) | [270](/filings/0001723128-25-000062.md) | [263 d](/filings/0001723128-26-000011.md) | [256](/filings/0001723128-26-000020.md) | [286](/filings/0001723128-26-000031.md) | [274](/filings/0001723128-25-000062.md) | [297 d](/filings/0001723128-26-000011.md) | [320](/filings/0001723128-26-000020.md) | [335](/filings/0001723128-26-000031.md) |
| Research and development | $m | [41.4](/filings/0001723128-24-000042.md) | [46.1 d](/filings/0001723128-26-000011.md) | [39.3](/filings/0001723128-25-000022.md) | [36.1](/filings/0001723128-25-000047.md) | [61.1](/filings/0001723128-25-000062.md) | [54.3 d](/filings/0001723128-26-000011.md) | [40.0](/filings/0001723128-26-000020.md) | [48.0](/filings/0001723128-26-000031.md) | [63.4](/filings/0001723128-25-000062.md) | [34.8 d](/filings/0001723128-26-000011.md) | [38.4](/filings/0001723128-26-000020.md) | [39.0](/filings/0001723128-26-000031.md) |
| Selling, general and administrative | $m | [113](/filings/0001723128-24-000042.md) | [109 d](/filings/0001723128-26-000011.md) | [113](/filings/0001723128-25-000022.md) | [116](/filings/0001723128-25-000047.md) | [119](/filings/0001723128-25-000062.md) | [129 d](/filings/0001723128-26-000011.md) | [118](/filings/0001723128-26-000020.md) | [124](/filings/0001723128-26-000031.md) | [138](/filings/0001723128-25-000062.md) | [146 d](/filings/0001723128-26-000011.md) | [139](/filings/0001723128-26-000020.md) | [149](/filings/0001723128-26-000031.md) |
| Operating income | $m | [75.6](/filings/0001723128-24-000042.md) | [14.2 d](/filings/0001723128-26-000011.md) | [(10.7)](/filings/0001723128-25-000022.md) | [95.5](/filings/0001723128-25-000047.md) | [88.8](/filings/0001723128-25-000062.md) | [75.8 d](/filings/0001723128-26-000011.md) | [100](/filings/0001723128-26-000020.md) | [111](/filings/0001723128-26-000031.md) | [70.3](/filings/0001723128-25-000062.md) | [112 d](/filings/0001723128-26-000011.md) | [142](/filings/0001723128-26-000020.md) | [130](/filings/0001723128-26-000031.md) |
| Income tax | $m | [(2.1)](/filings/0001723128-24-000042.md) | [9.9 d](/filings/0001723128-26-000011.md) | [6.2](/filings/0001723128-25-000022.md) | [3.6](/filings/0001723128-25-000047.md) | [3.7](/filings/0001723128-25-000062.md) | [5.4 d](/filings/0001723128-26-000011.md) | [12.9](/filings/0001723128-26-000020.md) | [16.1](/filings/0001723128-26-000031.md) | [(23.4)](/filings/0001723128-25-000062.md) | [5.7 d](/filings/0001723128-26-000011.md) | [2.2](/filings/0001723128-26-000020.md) | [1.4](/filings/0001723128-26-000031.md) |
| Net income | $m | [9.7](/filings/0001723128-24-000042.md) | [(98.6) d](/filings/0001723128-26-000011.md) | [(91.6)](/filings/0001723128-25-000022.md) | [6.0](/filings/0001723128-25-000047.md) | [(0.2)](/filings/0001723128-25-000062.md) | [(31.1) d](/filings/0001723128-26-000011.md) | [12.2](/filings/0001723128-26-000020.md) | [22.4](/filings/0001723128-26-000031.md) | [2.4](/filings/0001723128-25-000062.md) | [35.1 d](/filings/0001723128-26-000011.md) | [62.3](/filings/0001723128-26-000020.md) | [57.7](/filings/0001723128-26-000031.md) |
| Diluted EPS | $ per share | [0.06](/filings/0001723128-24-000042.md) | not reported | [(0.30)](/filings/0001723128-25-000022.md) | [0.02](/filings/0001723128-25-000047.md) | [0.00](/filings/0001723128-25-000062.md) | not reported | [0.04](/filings/0001723128-26-000020.md) | [0.07](/filings/0001723128-26-000031.md) | [0.01](/filings/0001723128-25-000062.md) | not reported | [0.19](/filings/0001723128-26-000020.md) | [0.18](/filings/0001723128-26-000031.md) |
| Basic EPS | $ per share | [0.06](/filings/0001723128-24-000042.md) | not reported | [(0.30)](/filings/0001723128-25-000022.md) | [0.02](/filings/0001723128-25-000047.md) | [0.00](/filings/0001723128-25-000062.md) | not reported | [0.04](/filings/0001723128-26-000020.md) | [0.07](/filings/0001723128-26-000031.md) | [0.01](/filings/0001723128-25-000062.md) | not reported | [0.20](/filings/0001723128-26-000020.md) | [0.18](/filings/0001723128-26-000031.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [86.9](/filings/0001723128-24-000042.md) | [91.5](/filings/0001723128-26-000011.md) | [46.5](/filings/0001723128-25-000022.md) | [43.8](/filings/0001723128-25-000047.md) | [74.0](/filings/0001723128-25-000062.md) | [111](/filings/0001723128-26-000011.md) | [59.2](/filings/0001723128-26-000020.md) | [71.5](/filings/0001723128-26-000031.md) | [201](/filings/0001723128-25-000062.md) | [282](/filings/0001723128-26-000031.md) | [198](/filings/0001723128-26-000020.md) | [128](/filings/0001723128-26-000031.md) |
| Current assets | $m | [1,456](/filings/0001723128-23-000044.md) | [1,378](/filings/0001723128-25-000012.md) | [1,380](/filings/0001723128-24-000021.md) | [1,485](/filings/0001723128-24-000032.md) | [1,513](/filings/0001723128-24-000042.md) | [1,588](/filings/0001723128-26-000011.md) | [1,510](/filings/0001723128-25-000022.md) | [1,585](/filings/0001723128-25-000047.md) | [1,838](/filings/0001723128-25-000062.md) | [1,911](/filings/0001723128-26-000031.md) | [1,798](/filings/0001723128-26-000020.md) | [1,947](/filings/0001723128-26-000031.md) |
| Total assets | $m | [3,687](/filings/0001723128-23-000044.md) | [3,473](/filings/0001723128-25-000012.md) | [3,456](/filings/0001723128-24-000021.md) | [3,510](/filings/0001723128-24-000032.md) | [3,461](/filings/0001723128-24-000042.md) | [3,501](/filings/0001723128-26-000011.md) | [3,365](/filings/0001723128-25-000022.md) | [3,423](/filings/0001723128-25-000047.md) | [3,600](/filings/0001723128-25-000062.md) | [3,678](/filings/0001723128-26-000031.md) | [3,540](/filings/0001723128-26-000020.md) | [3,776](/filings/0001723128-26-000031.md) |
| Current liabilities | $m | [761](/filings/0001723128-23-000044.md) | [847](/filings/0001723128-25-000012.md) | [834](/filings/0001723128-24-000021.md) | [1,114](/filings/0001723128-24-000032.md) | [1,095](/filings/0001723128-24-000042.md) | [1,130](/filings/0001723128-26-000011.md) | [1,076](/filings/0001723128-25-000022.md) | [1,107](/filings/0001723128-25-000047.md) | [862](/filings/0001723128-25-000062.md) | [882](/filings/0001723128-26-000031.md) | [728](/filings/0001723128-26-000020.md) | [883](/filings/0001723128-26-000031.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | [2,542](/filings/0001723128-23-000044.md) | [2,386](/filings/0001723128-25-000012.md) | [2,378](/filings/0001723128-24-000021.md) | [2,178](/filings/0001723128-24-000032.md) | [2,170](/filings/0001723128-24-000042.md) | [2,162](/filings/0001723128-26-000011.md) | [2,154](/filings/0001723128-25-000022.md) | [2,146](/filings/0001723128-25-000047.md) | [2,567](/filings/0001723128-25-000062.md) | [2,565](/filings/0001723128-26-000031.md) | [2,566](/filings/0001723128-26-000020.md) | [2,564](/filings/0001723128-26-000031.md) |
| Current portion of debt | $m | [30.5](/filings/0001723128-23-000044.md) | [34.1](/filings/0001723128-25-000012.md) | [33.7](/filings/0001723128-24-000021.md) | [225](/filings/0001723128-24-000032.md) | [225](/filings/0001723128-24-000042.md) | [224](/filings/0001723128-26-000011.md) | [31.8](/filings/0001723128-25-000022.md) | [31.2](/filings/0001723128-25-000047.md) | [7.2](/filings/0001723128-25-000062.md) | [6.8](/filings/0001723128-26-000031.md) | [6.2](/filings/0001723128-26-000020.md) | [6.0](/filings/0001723128-26-000031.md) |
| Shareholders' equity | $m | [331](/filings/0001723128-23-000044.md) | [19.8](/filings/0001723128-25-000012.md) | [(63.7)](/filings/0001723128-24-000021.md) | [(57.5)](/filings/0001723128-24-000032.md) | [(93.4)](/filings/0001723128-24-000042.md) | [(109)](/filings/0001723128-26-000011.md) | [(132)](/filings/0001723128-25-000022.md) | [(112)](/filings/0001723128-25-000047.md) | [(109)](/filings/0001723128-25-000062.md) | [(70.8)](/filings/0001723128-26-000031.md) | [(45.4)](/filings/0001723128-26-000020.md) | [33.0](/filings/0001723128-26-000031.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [81.4 d](/filings/0001723128-24-000042.md) | [136 d](/filings/0001723128-26-000011.md) | [(4.4)](/filings/0001723128-25-000022.md) | [39.7 d](/filings/0001723128-25-000047.md) | [142 d](/filings/0001723128-25-000062.md) | [118 d](/filings/0001723128-26-000011.md) | [7.4](/filings/0001723128-26-000020.md) | [83.8 d](/filings/0001723128-26-000031.md) | [118 d](/filings/0001723128-25-000062.md) | [130 d](/filings/0001723128-26-000011.md) | [(26.7)](/filings/0001723128-26-000020.md) | [(21.2) d](/filings/0001723128-26-000031.md) |
| Capital expenditure | $m | [11.7 d](/filings/0001723128-24-000042.md) | [9.9 d](/filings/0001723128-26-000011.md) | [9.2](/filings/0001723128-25-000022.md) | [10.6 d](/filings/0001723128-25-000047.md) | [16.9 d](/filings/0001723128-25-000062.md) | [15.2 d](/filings/0001723128-26-000011.md) | [13.2](/filings/0001723128-26-000020.md) | [22.8 d](/filings/0001723128-26-000031.md) | [12.3 d](/filings/0001723128-25-000062.md) | [21.8 d](/filings/0001723128-26-000011.md) | [8.2](/filings/0001723128-26-000020.md) | [30.7 d](/filings/0001723128-26-000031.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [151](/filings/0001723128-23-000044.md) | [152](/filings/0001723128-24-000021.md) | [155](/filings/0001723128-24-000032.md) | [160](/filings/0001723128-24-000042.md) | [307](/filings/0001723128-25-000022.md) | [319](/filings/0001723128-25-000047.md) | [310](/filings/0001723128-25-000062.md) | [324](/filings/0001723128-26-000020.md) | [322](/filings/0001723128-26-000031.md) | [325](/filings/0001723128-25-000062.md) | [329](/filings/0001723128-26-000020.md) | [328](/filings/0001723128-26-000031.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 319,353,919 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001723128-26-000031.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:46 ET. No prices; not investment advice.